YAP1 and neoplasm: Axl is required for YAP/TAZ-dependent tumor cell invasion, proliferation, tumorigenicity, and resistance to EGFR inhibitors [91,351,352,353,354], and Axl inhibitors have performed well in pre-clinical trials [355].